FLASH radiotherapy: State-of-the-art 2021–2022 (notice n° 504545)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01853cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121083952.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Verrelle, Pierre |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | FLASH radiotherapy: State-of-the-art 2021–2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 51 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Irreversible damage is one of the main limitations of external beam radiotherapy. FLASH radiotherapy (RT), which delivers ultra-high dose rate radiation to the target, could be a promising strategy to circumvent this issue. In FLASH-RT, a radiation dose of 5 to 15 Gy is delivered in a single microsecond pulse or as a series of pulses administered in sequence, each lasting ≤100 milliseconds. In mouse models, FLASH-RT has been shown to significantly reduce lung fibrosis while maintaining its antitumoral effects. This sparing of normal tissue from radio-induced injury has been confirmed in all organs investigated so far in both mice and large mammals, making FLASH-RT an attractive treatment approach in anticancer radiotherapy. The molecular mechanisms underlying the effects of FLASH-RT remain only partially understood. However, the evidence that this technique spares healthy tissues, especially progenitor cells, is compelling. Large companies are becoming interested in new-generation accelerators dedicated to FLASH-RT and several clinical trials have already been designed. It is hoped that the use of FLASH-RT in clinical practice will expand the indications for curative radiotherapy, particularly in children. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fouillade, Charles |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Favaudon, Vincent |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 8 | 2 | 2022-03-01 | p. 98-104 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-2-page-98?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-2-page-98?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux